Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation
|ClinicalTrials.gov Identifier: NCT01707368|
Recruitment Status : Completed
First Posted : October 16, 2012
Last Update Posted : October 30, 2014
|Condition or disease||Intervention/treatment|
|Psoriasis Vulgaris Plaque Psoriasis||Drug: Daivobet® Gel|
|Study Type :||Observational|
|Actual Enrollment :||561 participants|
|Official Title:||Course of Psoriasis During Long Term Treatment With Calcipotriol Plus Betamethasone in Gel Formulation|
|Study Start Date :||October 2012|
|Primary Completion Date :||May 2014|
|Study Completion Date :||July 2014|
all eligible patients
Daivobet® Gel once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
Drug: Daivobet® Gel
Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
- The course of disease and relapse management during treatment with Daivobet® Gel under consideration of patient`s individual application habits under daily use conditions. [ Time Frame: 1 year ]Number of exacerbations and relapses during one year observation time
- Physician's global Assessment of psoriasis vulgaris [ Time Frame: 1 year ]Assessment on 6-step scale from "no visible disease (O)" to "very severe disease (5)
- Side effects [ Time Frame: 1 year ]Number of participants with serious and non-serious adverse drug reactions, according to organ classes.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01707368
|PD Dr. med. Rosenbach|
|Osnabrück, Niedersachsen, Germany, 49078|
|Principal Investigator:||Thomas Rosenberg, PD Dr. med.||private practise, D- 49078 Osnabrück, Germany|